Baird RD et al. Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1. Clin Cancer Res 2025;31(20):4244-54. Abstract
Bardia A et al. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global phase III lidERA Breast Cancer trial. San Antonio Breast Cancer Symposium 2025;Abstract GS1-10.
Basu GD et al. Characterization of ESR1 alterations in patients with breast and gynecologic cancers. Breast Cancer Res 2026;28(1):40. Abstract
Bidard F et al. Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC). San Antonio Breast Cancer Symposium 2025;Abstract RF7-03.
Cabel L et al. Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. Ann Oncol 2026;37(3):329-40. Abstract
Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase III EMBER-3 trial. Ann Oncol 2026;37(4):532-43. Abstract
Lloyd MR et al. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res 2026;32(1):169-78. Abstract
Manich CS et al. Imlunestrant (Imlu) with or without abemaciclib (Abema) in advanced breast cancer (ABC): A subgroup analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients (pts) from EMBER-3. ESMO Breast 2025;Abstract 297O.
Mayer E et al. Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i): Primary results of the phase III evERA BC trial. ESMO 2025;Abstract LBA16.
Neven P et al. Imlunestrant with or without abemaciclib as first- and second-line therapy in advanced breast cancer (ABC): A subgroup analysis from the EMBER-3 trial. ESMO Breast 2025;Abstract 306P.
O’Shaughnessy J et al. Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial. ASCO 2025;Abstract 1060.
Robertson JFR et al. Pharmacodynamics of camizestrant treatment in postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer: Results from the randomized, presurgical SERENA-3 study. J Clin Oncol 2026;44(9):750-61. Abstract
Rugo H et al. Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Phase 2 results from ELEVATE, an open-label, umbrella study. San Antonio Breast Cancer Symposium 2025;Abstract RF7-01.
Rugo HS et al. Real-world outcomes of elacestrant in ER+, HER2-, ESR1-mutant metastatic breast cancer. Clin Cancer Res 2026;32(1):179-87. Abstract
Rugo HS et al. Clinical and biomarker subgroup analysis of evERA Breast Cancer: A phase III trial of giredestrant plus everolimus in patients with estrogen receptor-positive, HER2-negative advanced breast cancer previously treated with a CDK4/6 inhibitor. San Antonio Breast Cancer Symposium 2025;Abstract GS3-09.
Vidal M et al. Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: Results from the preoperative window-of-opportunity ELIPSE trial. Clin Cancer Res 2025;31(7):1223-32. Abstract